OBJECT Petroclival meningiomas are among the most challenging intracranial tumors to treat surgically. Many skull base approaches have been described to improve resection and decrease patient morbidity. The authors undertook this study to evaluate the results of their treatment of petroclival meningiomas using objective measurements of tumor volume and a new impairment scoring system to assess neurological symptoms that severely affect the patient's quality of life, such as impairment of swallowing and speaking, motor function, and consciousness and communication. METHODS Between January 1990 and December 2009, the authors used a combined transpetrosal approach to treat 60 patients with benign (WHO Grade I) petroclival meningiomas. In this retrospective study, all 60 cases were analyzed in detail with regard to tumor volume, extent of resection (EOR), long-term tumor control, neurological outcome, and the patient condition. In addition, patients were divided into 2 groups according to the period during which the surgery was performed: the early group, from 1990 to 1999, and the late group, from 2000 to 2009. A new scoring system, the petroclival meningioma impairment scale (PCMIS), was created for quantitative assessment of 8 categories of neurological functions, with scores assigned in each category according to the level of disability and its impact on the patient. The PCMIS was used preoperatively, at 3 months after surgery, and at the time of the last follow-up examination, and the results for the 2 groups were compared. RESULTS There were 24 cases in the early group (1990–1999), and the mean duration of follow-up was 149.3 months. The mean EOR was 96.1%, and good long-term tumor control was obtained in 22 patients (91.7%). One of patients died because of a postoperative complication in the perioperative period. The PCMIS improved in 3 patients (12.5%), remained stable in 1 (4.2%), and worsened in 20 (83.3%). There were 36 cases in the late group (2000–2009), and the mean duration of follow-up was 77.9 months. The mean EOR was 92.7%, and good long-term tumor control was obtained in 34 patients (94.4%). The PCMIS score improved in 23 patients (63.9%), remained stable in 5 (13.9%), and worsened in 8 (22.2%). CONCLUSIONS The combined transpetrosal approach has provided satisfactory functional improvements and excellent tumor control for patients with petroclival meningiomas. The PCMIS provides a specific tool for quantitative assessment of the patient's state.
Although entire exposure of the sigmoid sinus has been recognized as a complicated procedure in presigmoid approaches, we developed a new technique to expose the sigmoid sinus quite safely and simply without tough bone work. This study aims to demonstrate our technique in detail and present the effect of the procedure. Between January 2004 and December 2010, 77 patients underwent operations via presigmoid approaches in our institute. In all cases, the sigmoid sinus was completely exposed with our new surgical technique. The key step to expose the sigmoid sinus in our technique is dissection of the sinus from the overlying inner cortical bone in an antegrade direction from the junction of the transverse-sigmoid sinus to the jugular bulb using a bone dissector, avoiding meticulous bone drilling. We retrospectively examined a surgical video of all cases and determined the operative time required to entirely expose the sigmoid sinus from the transverse-sigmoid junction to the jugular bulb. In all 77 cases, the sigmoid sinuses were safely exposed with our new technique, and there was no episode of sinus injury. The operative time required to expose the sigmoid sinus ranged from 9.4 to 28.2 min (mean, 14.5 min). Standard drilling techniques took 32.3 min (range, 18.4-46.6 min) in last 20 cases before adoption of new technique. The new technique significantly shortened the surgical time to expose the sigmoid sinus (p < 0.01, Welch's t test). Our new technique is very useful for safely and simply exposing the sigmoid sinus, especially for standard neurosurgeons.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.